Granlibakken Tahoe Floorplan

Registered Attendees


Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:

  • Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting (You can edit your own abstract from My Account page as well)

    NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.

  • Full participant list, including joint meeting participants
  • Printable Invoices and Invitation Letters
  • Scholarship Information
  • Lodging Information

Login to My Account page

This meeting took place in 2015



For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.

Pathways of Neurodevelopmental Disorders (C8)


Organizer(s) Randi J. Hagerman, Mustafa Sahin and Paul J. Hagerman
March 16—20, 2015
Granlibakken Tahoe • Tahoe City, California USA
Discounted Abstract Deadline: Nov 18, 2014
Abstract Deadline: Dec 16, 2014
Scholarship Deadline: Nov 18, 2014
Discounted Registration Deadline: Jan 15, 2015

Sponsored by BioLegend, Inc., California Institute for Regenerative Medicine (CIRM), Curemark LLC and FORUM Pharmaceuticals Inc.

Summary of Meeting:
Advances in genetics and animal models for many neurodevelopmental disorders have led to the development of targeted treatments that can reverse neurobiological abnormalities in the animal models. Human studies have begun to show significant benefit from targeted treatments for several neurodevelopmental disorders including fragile X syndrome, tuberous sclerosis, Angelman Syndrome, Down Syndrome, Rett Syndrome and neurofibromatosis, with the potential for many more. There are remarkable commonalities in the dysfunction of key pathways and the molecular mechanisms involved in synaptic plasticity across neurodevelopmental disorders. This Keystone Symposia meeting covers advances in targeted treatments for several neurodevelopmental disorders with an emphasis on common pathways across disorders and treatments that may help more than one disorder. The conference also addresses the gap between how environmental factors including seizures and toxins can impact genetically vulnerable populations, such as those with neurodevelopmental problems, and the molecular mechanisms including mitochondrial dysfunction, oxidative stress, miRNA dysregulation and neuroinflammation that are involved. The goal of this conference is to stimulate development of new treatments and biomarkers to assess treatments in neurodevelopmental disorders and to promote early intervention with prophylactic and targeted treatments. By pulling together basic science and translational clinical trials, and mixing clinicians with molecular biologists and neurobiologists, the meeting should foster new ideas for treatment that will be beneficial across the spectrum of neurodevelopmental disorders.

View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference

Conference Program    Print  |   View meeting in 12 hr (am/pm) time


MONDAY, MARCH 16

16:00—20:00
Arrival and Registration

Pre Function
18:00—20:00
Welcome Mixer
No registration fees are used to fund alcohol served at this function.

Granhall
18:00—20:00
Light Meal - Provided by Granlibakken

Granhall

TUESDAY, MARCH 17

07:00—08:00
Breakfast

Granhall
08:00—08:15
Welcome Remarks
Meeting has ended...abstracts no longer viewable online.

Mountain/Lake
Randi J. Hagerman, University of California, Davis Health System, USA

Mustafa Sahin, Boston Children's Hospital, USA

Paul J. Hagerman, University of California, Davis, USA

08:15—09:15
Keynote Address
Meeting has ended...abstracts no longer viewable online.

Mountain/Lake
Eric Klann, New York University, USA
Translating Translational Control in Multiple Neurodevelopmental Disorders

09:15—11:45
Targeted Treatments
Meeting has ended...abstracts no longer viewable online.

Mountain/Lake
* Paul J. Hagerman, University of California, Davis, USA

Mustafa Sahin, Boston Children's Hospital, USA
Targeted Treatments for Tuberous Sclerosis

Walter Kaufmann, Boston Children's Hospital, USA
Targeted Treatments for Rett Syndrome: The IGF-1 Experience

Randi J. Hagerman, University of California, Davis Health System, USA
Targeted Treatments for Fragile X Syndrome

William C. Mobley, University of California, San Diego, USA
Exploring the Biology of Alzheimer Disease in the Context of Down Syndrome

09:40—10:00
Coffee Break

Pre Function
11:45—13:00
Poster Setup

Bay
13:00—22:00
Poster Viewing

Bay
11:45—17:00
On Own for Lunch

16:30—17:00
Coffee Available

Pre Function
17:00—19:00
Emerging Targeted Treatments
Meeting has ended...abstracts no longer viewable online.

Mountain/Lake
* Mriganka Sur, Massachusetts Institute of Technology, USA

Katherine A. Rauen, University of California, Davis MIND Institute, USA
Treating RASopathies

Edwin J. Weeber, University of South Florida, USA
Targeted Treatment of Angelman Syndrome

Stephane J. Baudouin, Cardiff University, UK
Targeting MAP-Kinase Interacting Kinases Restores Protein Synthesis Homeostasis and Improves Behavioral Deficits in Neuroligin-3 Mouse Model of Autism

Gabriella D'Arcangelo, Rutgers University, USA
Short Talk: Complex Neurological Phenotype in Mutant Mice Lacking Tsc2 in Excitatory Neurons of the Developing Forebrain

19:00—20:00
Dinner

Granhall
19:30—22:00
Poster Session 1

Bay
20:00—21:00
Social Hour
No registration fees are used to fund alcohol served at this function.

Bay

WEDNESDAY, MARCH 18

07:00—08:00
Breakfast

Granhall
08:00—11:15
RNA Toxicity and Mitochondrial Dysfunction Across Neurodevelopmental Disorders
Meeting has ended...abstracts no longer viewable online.
This session reviews the RNA toxicity mechanisms and mitochondrial dysfunction in neurodevelopmental disorders including miRNA dysregulation.

Mountain/Lake
* Randi J. Hagerman, University of California, Davis Health System, USA

Paul J. Hagerman, University of California, Davis, USA
RNA Toxicity in Fragile X Premutation Disorders in Development and Aging

Claes Wahlestedt, University of Miami, Miller School of Medicine, USA
Understanding and Drugging the Epigenome

Douglas C. Wallace, Children's Hospital of Philadelphia, USA
A Mitochondrial Dysfunction in Neurodevelpmental Disorders

Gul Dolen, Johns Hopkins University, USA
Social Reward: Basic Mechanisms and Autism Pathogenesis

Koh-ichi Nagata, Institute for Developmental Research, Aichi Human Service Center, Japan
Short Talk: Comprehensive Approach with an Analytical Battery to Understand Pathophysiological Role of A2BP1/RBFOX1, a "Hub" Gene in the ASD Gene Transcriptome network

Christina Gross, Cincinnati Children's Hospital Medical Center, USA
Short Talk: Crucial Roles of the PI3K Complex Components PIKE and p110beta in Impaired Neuronal Function, Behavior and Cognition in Fragile X Syndrome

09:20—09:40
Coffee Break

Pre Function
11:15—13:00
Poster Setup

Bay
13:00—22:00
Poster Viewing

Bay
11:15—17:00
On Own for Lunch

15:00—16:30
Workshop: The Promise of Stem Cell Research for Neurodevelopmental Disorders. Organized in collaboration with the California Institute for Regenerative Medicine (CIRM)

Mountain/Lake
* Mani Vessal, California Institute for Regenerative Medicine, USA

Michael F. Clarke, Stanford University, USA
Molecular Regulation of Stem Cells in Down Syndrome

Flora M. Vaccarino, Yale University School of Medicine, USA
Modeling Early Cortical Development in Autism Spectrum Disorders Using iPSCs

Steve Fancy, University of California, San Francisco, USA
A New Model of Oligodendrocyte Dispersal throughout the Developing CNS

17:00—17:30
Coffee Available

Pre Function
17:30—19:15
Neurobiological Consequences of Seizures
Meeting has ended...abstracts no longer viewable online.
This session focuses on the neurobiological effects of seizures and their influence on the cognitive and behavioral phenotype of neurodevelopmental disorders.

Mountain/Lake
* Eric Klann, New York University, USA

Nael Burnashev, INSERM, France
Tuberous Sclerosis Complex: A Role of NMDA Receptor Subunits in Early Epilepsy

Timothy A. Benke, University of Colorado Denver, USA
Early-Life Seizures Cause Latent Synaptic Changes in FMRP-Mediated Signaling, Altered Synaptic Plasticity and an Autistic Phenotype

Kevin R. Francis, National Institute of Child Health and Human Development, USA
Short Talk: Identification of Neural Phenotypes and Causative Signaling Defects associated with Disorders of Cholesterol Synthesis Using Human iPSCs

Seung Tae Baek, Rockefeller University, USA
Short Talk: An AKT3-FOXG1-Reelin Network Underlies Human Focal Malformations of Cortical Development

19:15—20:15
Dinner

Granhall
19:30—22:00
Poster Session 2

Bay
20:00—21:00
Social Hour
No registration fees are used to fund alcohol served at this function.

Bay

THURSDAY, MARCH 19

07:00—08:00
Breakfast

Granhall
08:00—11:15
Epigenetic Changes and Environmental Toxicity in Neurodevelopmental Disorders
Meeting has ended...abstracts no longer viewable online.
This session explores epigenetic changes in neurodevelopmental disorders and the influence of environmental toxicity.

Mountain/Lake
* Randi J. Hagerman, University of California, Davis Health System, USA

Mriganka Sur, Massachusetts Institute of Technology, USA
Signaling and Circuit Mechanisms of Rett Syndrome

Isaac N. Pessah, University of California, Davis, USA
Tipping the Balance of Neural Circuits during Neurodevelopment: Toward Understanding Convergent Mechanisms from Genes and Environment

Anne E. West, Duke University Medical Center, USA
Epigenomic Regulation of Neuronal Differentiation

Zhaolan (Joe) Zhou, University of Pennsylvania, USA
Understanding the Role of Methyl-CpG Binding Domain Proteins in the Etiology of Autism Spectrum Disorders

Hyang Mi Moon, Stanford University, USA
Short Talk: Interaction between GABRB3 Haploinsufficiency and Gestational Lipopolysaccharide Exposure Exacerbates Placental Vulnerability

T. Peter Stein, Rowan University, USA
Short Talk: Bisphenol A (BPA) and Autism Spectrum Disorders

09:20—09:40
Coffee Break

Pre Function
11:15—17:00
On Own for Lunch

16:30—17:00
Coffee Available

Pre Function
17:00—18:45
Emerging New Treatments and Biomarkers
Meeting has ended...abstracts no longer viewable online.
This session focuses on new targeted treatments for neurodevelopmental disorders and potential biomarkers to be used in treatment studies.

Mountain/Lake
* Mustafa Sahin, Boston Children's Hospital, USA

Flora Tassone, University of California, Davis, USA
Biomarkers for Targeted Treatments in Fragile X Syndrome and Associated Disorders

Jason Arsenault, University of Toronto, Canada
Short Talk: Adeno-Associated Viral Vector-Mediated Gene Therapy Strategies to Treat Fragile X Syndrome

Samuel S.-H. Wang, Princeton University, USA
New Technologies for Probing Sensitive-Period Influences in Brain Development

18:45—19:00
Meeting Wrap-Up: Outcomes and Future Directions (Organizers)
Meeting has ended...abstracts no longer viewable online.

Mountain/Lake
19:00—20:00
Dinner

Granhall
19:00—20:00
Social Hour
No registration fees are used to fund alcohol served at this function.

Granhall
20:00—23:00
Entertainment
Entertainment is not subsidized by conference registration fees nor any U.S. federal government grants. Funding for this expense is provided by other revenue sources.

Granhall

FRIDAY, MARCH 20

 
Departure


*Session Chair †Invited, not yet responded.



We gratefully acknowledge support for this conference from:


Directors' Fund


These generous unrestricted gifts allow our Directors to schedule meetings in a wide variety of important areas, many of which are in the early stages of research.

Click here to view all of the donors who support the Directors' Fund.



Keystone Symposia thanks our Sponsors for generously supporting this meeting:

BioLegend, Inc. California Institute for Regenerative Medicine (CIRM)
Curemark LLC FORUM Pharmaceuticals Inc.

We gratefully acknowledge the generous grant for this conference provided by:


National Institutes of Health

Grant No. 1R13NS090680-01

The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.


We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:



Novartis Institutes for BioMedical Research


We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:

NeuroscientistNews S. Karger A.G - Developmental Neuroscience

Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:


Click here to view more of these organizations


If your organization is interested in joining these entities in support of Keystone Symposia, please contact: Sarah Lavicka, Director of Development, Email: sarahl@keystonesymposia.org,
Phone:+1 970-262-2690

Click here for more information on Industry Support and Recognition Opportunities.

If you are interested in becoming an advertising/marketing in-kind partner, please contact:
Yvonne Psaila, Director, Marketing and Communications, Email: yvonnep@keystonesymposia.org,
Phone:+1 970-262-2676